X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Trodelvy Returns For Gilead In Treatment Of Breast Cancer

Content Team by Content Team
9th September 2022
in Clinical Trials, News

After unimpressive evidence on tumour progression, many Gilead Sciences investors have stopped believing in Trodelvy in HR-positive, HER2-negative breast cancer. But now that the antibody-drug combination has unexpectedly returned, blockbuster dreams have been rekindled thanks to a life extension benefit that is better than expected by industry observers.

When used instead of the doctor’s preferred treatment for patients with extensively pretreated HR-positive, HER2-negative breast cancer, trodelvy increased patients’ lives by a median of 3.2 months. In the closely monitored TROPiCS-02 trial, those who took the TROP2-tagged medication lived an average of 14.4 months compared to 11.2 months for the chemotherapy group, which represents a 21% reduction in the chance of mortality.

Bill Grossman, M.D., Ph.D., the leader of Gilead Oncology’s therapeutic division, stated that they are hitting the upper end—if not exceeding—most of the predictions out there.

The RBC Capital Markets analysts’ earlier prediction of about 2.5 months, which was based on a poll of Gilead investors, was surpassed by the 3.2-month survival differential. The actual results also surpassed the investors’ expectations for Trodelvy to reach peak sales of at least $1 billion in the HR+/HER2-breast cancer market. Only 31% of investors surveyed by RBC thought Trodelvy could meet the requirement that Trodelvy demonstrate a survival advantage of more than 3 months in order to achieve that objective.

In a different RBC poll, physicians estimated that Trodelvy’s overall survival benefit needed to be roughly 2.5 months in order to be clinically significant. Debu Tripathy, M.D., head of breast medical oncology at the University of Texas MD Anderson Cancer Center, stated earlier that he would want to see a two-to three-month improvement at the very least.

Back in June, it was widely believed that Trodelvy’s meagre 1.5-month benefit in delaying tumour development or mortality lacked clinical significance. Trodelvy reduced the chance of death by 16% while increasing life span by only 1.6 months at the median at the time, when data on overall survival were still in their infancy.

In the 543-subject experiment, 293 patients had passed away at the time of the first intermediate analysis. Prior to the second interim analysis, Wall Street analysts and investors estimated that the TROPiCS-02 trial would result in 350 total deaths. 390 deaths were actually counted in the current analysis, which probably favoured Trodelvy in regards to data maturity.

Even so, doubling the survival advantage after just an additional 2.3 months of follow-up and 100 additional events was no small accomplishment, leading one to wonder if patient characteristics have changed in the new analysis.

More patients in the Trodelvy arm than in the control arm did not return in time for the analysis at the initial release at 10.2 months of follow-up, according to Gilead’s Grossman. It really just comes down to gathering all the events and having a more developed survival curve for them, he said. There’s nothing different about the patient demographics or anything like that, he said.

The FDA has received the updated results that Gilead submitted, but Grossman did not specify the line of treatment that Gilead is requesting.

Investors in Gilead may be pleased with Trodelvy’s new survival performance, but there is still plenty to be said about how it compares to AstraZeneca and Daiichi Sankyo’s Enhertu.

Enhertu just received FDA approval for previously treated HER2-low breast cancer, a first for the industry. Individuals who were previously categorised as HER2-negative fall under the newly created HER2-low category.

Gilead also presented a subgroup analysis of the TROPiCS-02 HER2-low population at ESMO 2022. There, compared to chemo, trodelvy reduced the chance of tumour growth or mortality by 42%. Compared to those who had chemotherapy, those who took Trodelvy lasted a median of 6.4 months without the disease getting worse. For individuals who were HER2-negative according to the new standard as determined by an IHC 0 test, the risk decrease was 28%.

In the DESTINY-Breast04 study, Enhertu reduced the risk of disease progression or death in HR-positive, HER2-low patients by 49%. Patients who took Enhertu lived 10.1 months without their disease getting worse, compared to 5.4 months for patients who received chemotherapy.

Grossman emphasised that even though all biopharma watchers are contrasting the two studies side by side, these are not apples-to-apples comparisons. Compared to Enhertu’s DESTINY-Breast04, Trodelvy’s TROPiCS-02 recruited a more advanced population that had had a median of three prior chemotherapies. Additionally, 100% of patients in TROPiCS-02 had previously received CDK4/6 inhibitor therapy, compared to 30% in the Enhertu trial.

They can enter the HER2-low population, in his opinion, just as well as Enhertu can, according to the subpopulation analysis, Grossman said. As an anti-TROP2 medication, Trodelvy may have the advantage of not necessarily requiring a HER2 diagnosis, he added.

Trodelvy is the focal point of Gilead’s developing solid tumour franchise. The medication has demonstrated efficacy in triple-negative breast cancer patients who had previously undergone two systemic treatments, at least one of which was for metastatic disease. Gilead is considering earlier therapy for both TNBC and HR+/HER2-breast cancer because of the encouraging preliminary clinical findings, according to Grossman.

When it comes to many different tumour types, they have established a solid, broad suite where they can look at orthogonal pairings that can really support Trodelvy, said Grossman. What one will see next is not only the drive into early lines of therapy with Trodelvy, but they will start seeing a lot of unique mixtures for distinction against their competitors emerge as well, said Grossman.

Previous Post

Empowering the healthcare fraternity through dynamic online courses

Next Post

With FDA Approval, Revance With Daxxify Will Rival Botox

Related Posts

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
Next Post
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

With FDA Approval, Revance With Daxxify Will Rival Botox

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In